Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2011 2
2012 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of human ocular distribution of bimatoprost and latanoprost.
Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA. Ichhpujani P, et al. J Ocul Pharmacol Ther. 2012 Apr;28(2):134-45. doi: 10.1089/jop.2011.0097. Epub 2011 Dec 2. J Ocul Pharmacol Ther. 2012. PMID: 22136089 Clinical Trial.
Concentrations of bimatoprost, bimatoprost acid, latanoprost, and latanoprost acid in the human aqueous and ocular tissues were measured using liquid chromatography tandem mass spectrometry. ...In this report, human ocular tissues were examined concurrently with aqu …
Concentrations of bimatoprost, bimatoprost acid, latanoprost, and latanoprost acid in the human aqueous and ocular tissues wer …
Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
Raber S, Courtney R, Maeda-Chubachi T, Simons BD, Freedman SF, Wirostko B; A6111139 Study Group. Raber S, et al. Ophthalmology. 2011 Oct;118(10):2022-7. doi: 10.1016/j.ophtha.2011.03.039. Epub 2011 Jul 23. Ophthalmology. 2011. PMID: 21788077 Clinical Trial.
MAIN OUTCOME MEASURES: Latanoprost acid plasma exposure. RESULTS: The evaluable PK analysis set included data from 39 of 47 enrolled subjects. ...Latanoprost acid was eliminated rapidly in all age groups and resulted in only a brief period of systemic …
MAIN OUTCOME MEASURES: Latanoprost acid plasma exposure. RESULTS: The evaluable PK analysis set included data from 39 of 47 en …
Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract.
Cantor LB, Hoop J, Wudunn D, Yung CW, Catoira Y, Valluri S, Cortes A, Acheampong A, Woodward DF, Wheeler LA. Cantor LB, et al. Br J Ophthalmol. 2007 May;91(5):629-32. doi: 10.1136/bjo.2006.110155. Epub 2006 Nov 29. Br J Ophthalmol. 2007. PMID: 17135335 Free PMC article. Clinical Trial.
After latanoprost treatment, the mean concentration of latanoprost acid (13,14-dihydro-17-phenyl trinor prostaglandin F2alpha) in aqueous samples was 29.1 nM at hour 1, 41.3 nM at hour 3 and 2.5 nM at hour 6. ...CONCLUSIONS: Low levels of bimatoprost acid were detec …
After latanoprost treatment, the mean concentration of latanoprost acid (13,14-dihydro-17-phenyl trinor prostaglandin F2alpha) …